source
- Pierre Fabre aligns with FDA on resubmission of Ebvallo cell therapyPierre Fabre Laboratories announced that it has reached an agreement with the U.S. Food and Drug Administration on a new path for its cell therapy Ebvallo, which had been rejected twice. The FDA w…
- Odyssey Therapeutics raises $279 million in IPO, begins Nasdaq tradingOdyssey Therapeutics, a biotech focused on autoimmune diseases, announced that its initial public offering generated $279 million. The company sold about 15.5 million shares and priced the IPO at…